Welcome to our dedicated page for Nls Pharmaceutics news (Ticker: NLSP), a resource for investors and traders seeking the latest updates and insights on Nls Pharmaceutics stock.
NLS Pharmaceutics Ltd. (NLSP) generates news that reflects both its historical role as a Swiss clinical-stage biopharmaceutical company focused on central nervous system disorders and its transformation through a merger with Kadimastem Ltd. into NewcelX Ltd. Company announcements and SEC filings describe a shift from a pure CNS small-molecule focus toward an integrated platform that also encompasses cell therapies for neurodegenerative and metabolic diseases.
News items associated with NLSP and the subsequent NewcelX name cover several recurring themes. Transaction-related updates include the approval and closing of the merger with Kadimastem, the 1-for-10 reverse share split, the name change to NewcelX Ltd., and the transition of the Nasdaq listing from NLSP to the new symbol NCEL. These releases explain the exchange ratio between NLS and Kadimastem shareholders, the resulting ownership structure, and the rationale for combining small-molecule and cell therapy pipelines.
Pipeline and R&D news highlights programs such as AstroRx® for ALS, the IsletRx stem cell–derived therapy for insulin-dependent diabetes, and the DOXA small-molecule platform for CNS and neurodegenerative indications. Announcements describe preclinical and clinical milestones, intellectual property developments such as a Hong Kong patent for IsletRx-related cell-selection and enrichment technology, and expansion of the DOXA platform through the AEX-6xx series developed with Aexon Labs.
Additional coverage includes strategic collaborations and governance updates. Examples are the collaboration framework between Kadimastem and TargetGene for gene-edited cell therapies, continued support from the BIRD Foundation for the ITOL-102 diabetes program, and appointments to leadership roles and the Scientific Advisory Board at NewcelX. For readers tracking NLSP-related news, this page offers a consolidated view of historical NLS announcements and the ongoing evolution of the combined company under the NewcelX name and NCEL ticker.
NLS Pharmaceutics Ltd. has received Orphan Drug Designation (ODD) from the FDA for its product candidate, Quilience® (Mazindol ER), aimed at treating Idiopathic Hypersomnia (IH). Currently, there is only one approved drug for IH in the U.S., highlighting a significant unmet medical need. The ODD provides NLS with seven years of marketing exclusivity and financial incentives. Quilience® has shown promising Phase 2a results in promoting wakefulness in narcolepsy patients, similar to IH, positioning the company to enhance shareholder value through its Mazindol-based solutions.
NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) received a delisting determination letter from Nasdaq on September 29, 2022, due to failure to meet the minimum stockholders' equity requirement. The company plans to request a hearing before the Nasdaq Hearings Panel, which could grant an extension to regain compliance by March 28, 2023. NLS Pharmaceutics is focused on developing therapies for central nervous system disorders, with its lead candidate, Quilience, showing positive results in clinical trials for narcolepsy.
NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) has announced a private placement for 5,194,802 common shares and warrants to purchase up to 2,597,401 common shares, raising approximately $4 million. The shares are priced at $0.77, a 20% premium over the previous closing price. The company plans to utilize the funds for the development of its lead product, Quilience®, for narcolepsy, and for general corporate purposes. The offering is expected to close by October 7, 2022. Existing short-term notes will convert into common shares and additional warrants.
NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) announced positive results from its Phase 2a trial of Quilience® (Mazindol ER) for treating excessive daytime sleepiness (EDS) and cataplexy in narcolepsy patients. The trial achieved its primary endpoint, showing a mean reduction of 7.1 points in EDS, significantly better than the 3.2 points for placebo (p=0.0081). The drug demonstrated rapid action and safety, with no serious adverse events reported. An open-label extension study indicated strong patient interest in continuing treatment, with interim results expected by year-end 2022.
NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) announced a Virtual Key Opinion Leader (KOL) Event to discuss top-line results from its Phase 2a clinical trial of Quilience (Mazindol ER) for excessive daytime sleepiness and cataplexy in narcolepsy patients. The event is scheduled for September 30, 2022. The Phase 2a trial enrolled 67 patients, evaluating the drug’s efficacy and safety. The primary endpoint assessed changes in excessive daytime sleepiness using the Epworth Sleepiness Scale, crucial for patients with narcolepsy types 1 and 2.
NLS Pharmaceutics Ltd. announced the appointment of Dr. George Apostol as Chief Medical Officer and Global Head of R&D, effective immediately. Dr. Apostol brings extensive experience in drug development from his previous role at Endo Pharmaceuticals. He expressed enthusiasm for overseeing the upcoming Phase 2a results of Quilience for narcolepsy treatment. Additionally, the company confirmed Sylvia Panigone will depart as COO on November 30, 2022. This leadership change aligns with NLS's objectives to advance Quilience towards pivotal trials and expand its CNS disorder pipeline.
NLS Pharmaceutics has received patent approval in Japan for its lead product, Quilience® (mazindol ER), which is being developed for ADHD, narcolepsy, and idiopathic hypersomnia. This adds to existing patents in the U.S., Europe, Canada, and South Korea, strengthening the company's market position. CEO Alex Zwyer expressed optimism about the company's robust patent estate and ongoing Phase 2a clinical trials for Quilience®. The company also holds Orphan Drug Designations in key markets, enhancing treatment accessibility for patients.
NLS Pharmaceutics announced that the European Medicines Agency (EMA) has issued a positive opinion to grant Orphan Drug Designation (ODD) for Mazindol ER (Quilience) in treating idiopathic hypersomnia (IH). This designation acknowledges the unmet medical needs of IH, a rare sleep disorder affecting approximately 156,000 individuals in Europe. The company anticipates enrolling patients in an expanded access program, which may generate non-dilutive revenue. NLS plans to report final results from its ongoing Phase 2a narcolepsy trial in September 2022.
NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) has received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement of $1.00 per share. The company has 180 days, until December 5, 2022, to regain compliance. If the share price meets the requirement for ten consecutive business days, the compliance matter will be resolved. Should compliance not be achieved, NLS could face delisting, though an extension period is possible. The company is engaged in developing therapies for rare CNS disorders with its lead product Quilience® currently in Phase 2a trials for narcolepsy.
NLS Pharmaceutics (NASDAQ: NLSP, NLSPW) has appointed Chad C. Hellmann as the new Chief Financial Officer, succeeding Subhasis Roy, who will assist in the transition until June 30, 2022. Hellmann, previously CFO at Arcus Ventures, brings critical experience in operational strategies and capital markets for life sciences. The company is poised for significant developments with the upcoming Phase 2a results for Quilience, a treatment for narcolepsy, which is anticipated next quarter. NLS aims to enhance shareholder value through innovative strategies and product advancement.